Description of multiparametric targeting techniques for stereotactic arrhythmia radioablation in refractory ventricular tachycardia: A quaternary medical center experience

Abstract

Background: Ventricular tachycardia (VT) is a potentially life-threatening arrhythmia which remains a major contributor to cardiac morbidity and mortality worldwide. Recently the use of stereotactic radiation has demonstrated efficacy, although standardization of methodology is lacking and variations in technique exist. In this paper, we discuss our outcomes as well as the various options available and the proposed indications for each.
Methods: 12-lead EKGs and device-obtained tracings were used to approximately localize the arrhythmogenic origin and to define the arrhythmic mechanism. When feasible, electrophysiology studies (EPS) with 3-D electroanatomic (EA) mapping during which a 3-D electroanatomic substrate map was created to delineate cardiac structures, identify areas of low voltage scar and confirm arrhythmic circuits. A 4-D cardiac magnetic resonance imaging (cMRI) or cardiac computed tomography (cCT) was performed to delineate cardiac geometry and structures. The Stereotactic arrhythmia radioablation (STAR) treatment plans delivered a total dose of 25 Gy in a single treatment fraction covering the entire arrhythmogenic target.
Results: Six of the nine patients showed a reduction in VT events at 6 weeks post STAR. One patient underwent cardiac transplantation two weeks following STAR. Excluding this patient from the analysis, all but one patient had a dramatic diminution in VT events (to 0) at 6 months post-procedure, including both patients with an LVAD. Six of the nine patients survived at least 4 months post procedure event free and 6 patients survive to date. The lone patient who did not respond died 13 months post procedure, however he had no further defibrillator discharges. Another patient died two months post procedure from uncontrolled multiple myeloma. One patient developed an asymptomatic pleural effusion, but no serious STAR-induced postoperative complications occurred.
Conclusions: STAR appears to be an effective therapy for refractory ventricular tachycardia, although long term data are still developing. Additional clinical trials and techniques are in development and STAR programs should be encouraged for additional well-equipped centers with experienced multidisciplinary clinicians.

Keywords

Radiation / Cardiac ablation / Ventricular tachycardia / Stereotactic / Arrhythmia

References

[1] Benito B, Josephson ME. Taquicardia ventricular en la enfermedad coronaria. Rev Esp Cardiol. 2012; 65: 939-955. PMid: 22951088. https://doi.org/10.1016/j.recesp.2012.03.027

[2] Sapp JL, Wells GA, Parkash R, et al. Ventricular Tachycardia Abla- tion versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016; 375: 111-121. PMid: 27149033. https://doi.org/10.1056/NEJMoa1513614

[3] Cuculich PS, Schill MR, Kashani R, et al. Noninvasive Cardiac Radi- ation for Ablation of Ventricular Tachycardia. N Engl J Med. 2017; 377: 2325-2336. PMid: 29236642. https://doi.org/10.1056/NEJMoa1613773

[4] Thosani A, Trombetta M, Shaw G, et al. Stereotactic arrhythmia radioablation for intramural basal septal ventricular tachycardia orig- inating near the His bundle. Hear Case Rep. 2021; 7: 246-250. PMid: 34026506. https://doi.org/10.1016/j.hrcr.2021.01.012

[5] Ipsen S, Blanck O, Oborn B, et al. Radiotherapy beyond cancer: target localization in real-time MRI and treatment planning for car- diac radiosurgery. Med Phys. 2014; 41: 120702. PMid: 25471947. https://doi.org/10.1118/1.4901414

[6] Robinson CG, Samson PP, Moore KMS, et al. Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia. Circulation. 2019; 139: 313-321. PMid: 30586734. https://doi.org/10.1161/CIRCULATIONAHA.118.038261

[7] Cvek J, Neuwirth R, Knybel L, et al. Cardiac Radiosurgery for Ma-lignant Ventricular Tachycardia. Cureus [Internet]. 2014 [cited 2023 Sep 4]. https://doi.org/10.7759/cureus.190

[8] Loo BW, Soltys SG, Wang L, et al. Stereotactic ablative radiother- apy for the treatment of refractory cardiac ventricular arrhythmia. Circ Arrhythm Electrophysiol. 2015; 8: 748-750. PMid: 26082532. https://doi.org/10.1161/CIRCEP.115.002765

[9] Miszczyk M, Jadczyk T, Gołba K, et al. Clinical Evidence behind Stereotactic Radiotherapy for the Treatment of Ventricular Tachycar- dia (STAR)-A Comprehensive Review. J Clin Med. 2021; 10: 1238. PMid: 33802802. https://doi.org/10.3390/jcm10061238

[10] Jumeau R, Ozsahin M, Schwitter J, et al. Rescue procedure for an electrical storm using robotic non-invasive cardiac radio-ablation. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2018; 128: 189-191. PMid: 29753550. https://doi.org/10.1016/j.radonc.2018.04.025

[11] Aguilar M, Qian PC, Boeck M, et al. The Rapidly-Developing Area of Radiocardiology: Principles, Complications and Applications of Ra- diotherapy on the Heart. Can J Cardiol. 2021; 37: 1818-1827. PMid: 34303782. https://doi.org/10.1016/j.cjca.2021.07.011

[12] van Leeuwen-Segarceanu EM, Bos WJW, Dorresteijn LDA, et al. Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. Cancer Treat Rev. 2011; 37: 391-403. PMid: 21333452. https://doi.org/10.1016/j.ctrv.2010.12.004

[13] Ruiz CR, Mesa-Pabón M, Soto K, et al. Radiation-Induced Coronary Artery Disease in Young Patients. Heart Views Off J Gulf Heart As- soc. 2018; 19: 23-26. PMid: 29876028. https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_64_17

[14] van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation Dose- Response Relationship for Risk of Coronary Heart Disease in Sur- vivors of Hodgkin Lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34: 235-243. PMid: 26573075. https://doi.org/10.1200/JCO.2015.63.4444

[15] Kim JS, Choi SW, Park YG, et al. Impact of High-Dose Irradiation on Human iPSC-Derived Cardiomyocytes Using Multi-Electrode Arrays: Implications for the Antiarrhythmic Effects of Cardiac Radioablation. Int J Mol Sci. 2021; 23: 351. PMid: 35008778. https://doi.org/10.3390/ijms23010351

[16] Zhang DM, Navara R, Yin T, et al. Cardiac radiotherapy induces electrical conduction reprogramming in the absence of transmu- ral fibrosis. Nat Commun. 2021; 12: 5558. PMid: 34561429. https://doi.org/10.1038/s41467-021-25730-0

[17] Kiani S, Kutob L, Schneider F, et al. Histopathologic and Ultra- structural Findings in Human Myocardium After Stereotactic Body Radiation Therapy for Recalcitrant Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2020; 13: e008753. PMid: 33031001. https://doi.org/10.1161/CIRCEP.120.008753

[18] Miszczyk M, Sajdok M, Nożyński J, et al. Histopathological Exami- nation of an Explanted Heart in a Long-Term Responder to Cardiac Stereotactic Body Radiotherapy (STereotactic Arrhythmia Radioab- lation). Front Cardiovasc Med. 2022; 9: 919823. PMid: 35872906. https://doi.org/10.3389/fcvm.2022.919823

[19] Sharma A, Wong D, Weidlich G, et al. Noninvasive stereotac- tic radiosurgery (CyberHeart) for creation of ablation lesions in the atrium. Heart Rhythm. 2010; 7: 802-810. PMid: 20156591. https://doi.org/10.1016/j.hrthm.2010.02.010

[20] Brownstein J, Afzal M, Okabe T, et al. Method and Atlas to Enable Targeting for Cardiac Radioablation Employing the American Heart Association Segmented Model. Int J Radiat Oncol. 2021; 111: 178-185. PMid: 33836242. https://doi.org/10.1016/j.ijrobp.2021.03.051

[21] Boda-Heggemann J, Blanck O, Mehrhof F, et al. Interdisciplinary Clinical Target Volume Generation for Cardiac Radioablation: Multi- center Benchmarking for the RAdiosurgery for VENtricular TAchy- cardia (RAVENTA) Trial. Int J Radiat Oncol. 2021; 110: 745-756. PMid: 33508373. https://doi.org/10.1016/j.ijrobp.2021.01.028

[22] Oh S, Trombetta M, Liu E. Stereotactic Arrhythmia Radioablation for Treating refractory Ventricular Tachycardia. Med Phys [Internet]. 2022; 49. [cited 2023 Sep 4].

[23] Biederman RW, Gevenosky L, Williams R, et al. The Additive Value of Pacemakers and Icds in the Mri Environment Over 18 Years; A Large, Prospective Observational Study. Circulation [Internet]. 2022; 146. [cited 2023 Sep 4]. https://doi.org/10.1161/circ.146.suppl_1.10610

[24] Miszczyk M, Sajdak M, Bednarek J, et al. Stereotactic manage- ment of arrhythmia-radiosurgery treatment of ventricular tachycardia (SMART-VT). results of a prospective trial. Radiat Onc. 2023; 188. PMid: 37597807. https://doi.org/10.1016/j.radonc.2023.109857

[25] van der Ree M, Dieleman E, Visser J, et al. Non-invasive stereo- tactic arrhythmia radiotherapy for ventricular tachycardia: results of the prospective STARNL-1 trial. Europace. 2023; 25(3): 1015-1024. PMid: 36746553. https://doi.org/10.1093/europace/euad020